CYMABAY THERAPEUTICS Reports Earnings Results for Second Quarter of Fiscal Year 2023

August 12, 2023

🌥️Earnings Overview

CYMABAY THERAPEUTICS ($NASDAQ:CBAY) reported total revenue of USD 31.0 million for the second quarter of their fiscal year 2023 on June 30, 2023, showing a considerable increase over the 0.0 million reported in the same quarter of the previous year. However, net income for the quarter was reported at USD -0.81 million, drastically lower than the -27.09 million reported in the corresponding quarter of the prior year.

Stock Price

The company’s stock opened at $12.6 and closed at $13.0, up by 2.6% compared to the previous closing price of 12.6. Analysts anticipate the company to report strong earnings growth in the coming quarters, as it has over the past two years. This is due to the company’s increasing presence in the market, providing innovative therapies for patients with a variety of diseases. CYMABAY THERAPEUTICS has developed new drugs and therapies to tackle diseases that were previously difficult to treat, such as metabolic and cardiovascular diseases. The company is also expanding its product portfolio to include new drugs and therapies for conditions like inflammatory bowel disease, multiple sclerosis, and cancer. This expansion is expected to drive further revenue growth for CYMABAY THERAPEUTICS in the future.

Moreover, CYMABAY THERAPEUTICS has a strong presence in the clinical research and development sector, which will provide additional opportunities for growth in the future. Overall, CYMABAY THERAPEUTICS’ second quarter earnings results have demonstrated that the company is in a strong position and has potential to expand further. Analysts expect that the company will continue to report strong earnings growth in upcoming quarters. Investors will likely be closely following the stock to ensure that CYMABAY THERAPEUTICS’ performance remains strong. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cymabay Therapeutics. More…

    Total Revenues Net Income Net Margin
    31.02 -80.72 -260.3%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cymabay Therapeutics. More…

    Operations Investing Financing
    -55.28 -56.12 94.13
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cymabay Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    226.65 118.24 1.11
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cymabay Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    0.0% -205.7%
    FCF Margin ROE ROA
    -179.2% -37.5% -17.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we recently conducted an analysis of CYMABAY THERAPEUTICS‘ wellness. Based on our Risk Rating, CYMABAY THERAPEUTICS is a medium risk investment in terms of financial and business aspects. We have detected two risk warnings in the balance sheet and cash flow statement. If you’re interested in getting more information about our findings, we invite you to register with us to check it out. We believe our assessment can help guide your investment decisions and provide you with the best possible outcome. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competition in the pharmaceutical industry is fierce. Companies are constantly vying for market share and mind share. CymaBay Therapeutics Inc is no exception. The company competes with Acumen Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Corvus Pharmaceuticals Inc. All of these companies are striving to develop the best products and therapies to help patients.

    – Acumen Pharmaceuticals Inc ($NASDAQ:ABOS)

    Acumen Pharmaceuticals Inc is a pharmaceutical company with a market cap of 322.81M as of 2022. The company has a Return on Equity of -9.46%. Acumen Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on the development and commercialization of prescription drugs for the treatment of serious and life-threatening diseases. The company’s product pipeline includes products for the treatment of cancer, infectious diseases, and cardiovascular and central nervous system disorders.

    – Rocket Pharmaceuticals Inc ($NASDAQ:RCKT)

    Roche Pharmaceuticals Inc is a global healthcare company that focuses on the research, development, manufacture and commercialization of innovative pharmaceutical and diagnostic products. Its products and services address the prevention, diagnosis and treatment of diseases in six therapeutic areas: immunology, oncology, infectious diseases, ophthalmology, neuroscience and transplantation. The company has a market cap of 1.32B as of 2022 and a ROE of -46.52%. Roche’s products and services are sold in over 150 countries through a network of more than 2,000 distributors and wholesalers.

    – Corvus Pharmaceuticals Inc ($NASDAQ:CRVS)

    Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapies. The company’s lead product candidate, CPI-444, is a small molecule antagonist of the adenosine A2A receptor being evaluated in a Phase 1/2 clinical trial in patients with various solid tumors, as well as in combination with other immuno-oncology agents.


    CYMABAY THERAPEUTICS reported their earnings for the second quarter of their 2023 fiscal year, with total revenue of USD 31.0 million, a very large increase compared to the same quarter of the prior year. Net income was reported at USD -0.81 million, a decrease from -27.09 million reported in the same quarter. Investors should be encouraged by the large increase in revenues as well as the decrease in net losses, but should further investigate what caused the decrease in net income to ensure long-term stability and growth.

    Recent Posts

    Leave a Comment